Greenwich LifeSciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
-$1.39next fiscal year
Monitoring Framework
Key Performance Indicators
FLAMINGO-01 Phase III Trial Screening Rate Annually80,000.0%Target: Maintain or exceed current annualized screening rate to support global site expansion
FLAMINGO-01 Phase III Trial Total Screened Patients Quarterly1.3KTarget: Continue screening to support randomized arms and potential expansion of non-HLA-A*02 arm
Unaudited Cash Balance Quarterly10.5MTarget: Maintain sufficient runway to fund Phase III clinical operations
Watch Items
- Filing of Delayed Form 10-K for Fiscal Year 2025Trigger: Completion of audit by the new auditor and coordination with the prior auditorAction: Resolve accounts payable adjustments and file the Form 10-K to regain compliance with Nasdaq listing rules
- Filing of Delayed Form 10-Q for Q1 2026Trigger: Filing of the 2025 Form 10-KAction: Prepare and submit the Q1 2026 quarterly report immediately following the 10-K filing
- Regulatory Approval for Randomized non-HLA-A*02 ArmTrigger: Feedback or formal approval from regulatory agencies (FDA/EMA)Action: Transition the fully enrolled open-label non-HLA-A*02 arm into a randomized controlled trial format
Research as of 20 Jun 2026